Autonomix finalizes design review of intravascular nerve sensing catheter

Autonomix (AMIX) Medical announced it has advanced its proprietary sensing catheter through a final design review in preparation for human clinical trials. Previous versions had been used in animal models to demonstrate the ability to detect nerve signals. This marks a major step forward on the Company’s path toward initiating U.S. clinical studies. “What sets Autonomix’s approach apart is the potential of our device to sense and process neural signals directly at the source, enabled by our proprietary microchip array. This sensing catheter is a cornerstone of our platform, designed to help physicians precisely locate target nerves, tailor ablation, and confirm efficacy in real time. Completing this design review milestone reinforces the strength of our development program and brings us closer to delivering safer, more effective treatment options for patients, while advancing value-creating milestones for our shareholders,” commented Brad Hauser, CEO of Autonomix. “The ability to map nerve activity in real time has the potential to transform the field of neuromodulation and pain treatment. We believe this represents a paradigm shift in therapeutic electrophysiology, and we look forward to building momentum towards the launch of our clinical trial to support a De Novo FDA submission.”